Ovarian Cancer: What You Need to Know

Ovarian cancer is a group of malignant tumors that arise from the cells of the ovaries, the female reproductive organs that produce eggs and hormones such as estrogen and progesterone. It is the fifth most common cause of cancerrelated death among women and often goes undetected until it has reached an advanced stage.

Types of Ovarian Cancer

There are several histologic subtypes, each with distinct characteristics:

• Epithelial ovarian cancer accounts for ~90% of cases. It originates from the surface cells covering the ovary. Subtypes include serous, mucinous, endometrioid, clearcell and transitional (Brenner) tumors.
• Germ cell tumors arise from the cells that would become eggs. Common in younger women and usually highly responsive to chemotherapy.
• Sexcord stromal tumors develop from the connective tissue that produces hormones. They can cause hormonal symptoms such as irregular bleeding.

Risk Factors

While the exact cause is unknown, certain factors increase the likelihood of developing ovarian cancer:

• Age most cases are diagnosed after age 50.
• Family history mutations in BRCA1, BRCA2, and other hereditary cancer genes raise risk.
• Reproductive history never having been pregnant, early menarche, or late menopause increase exposure to estrogen.
• Endometriosis especially the endometrioid and clearcell subtypes.
• Obesity excess body fat influences hormone levels.
• Hormone therapy longterm use of estrogenonly therapy may elevate risk.

Symptoms

Early ovarian cancer often produces vague or no symptoms. When they appear, they may include:

• Abdominal bloating or swelling
• Pelvic or lowerback pain
• Changes in bowel habits, such as constipation
• Early satiety or difficulty eating
• Unexplained weight loss
• Irregular menstrual bleeding
• Frequent urinary urgency

Because these signs can be mistaken for benign conditions, awareness and prompt evaluation are crucial.

Screening and Diagnosis

There is no universally accepted screening test for averagerisk women. However, the following methods are employed when suspicion arises:

• Transvaginal ultrasound visualizes ovarian size, shape and internal structures.
• Serum CA125 test measures a tumorassociated antigen; elevated levels are common but not specific.
• Pap smear and genetic testing can identify highrisk individuals.
• Diagnostic laparoscopy or laparotomy allows direct inspection and tissue sampling.
• Pathology microscopic examination determines subtype and grade.

Staging

The International Federation of Gynecology and Obstetrics (FIGO) stages ovarian cancer from I to IV:

• Stage I confined to one or both ovaries.
• Stage II spread to pelvic organs.
• Stage III involvement of the peritoneum or regional lymph nodes.
• Stage IV distant metastasis, often to the liver or lungs.

Stage at diagnosis heavily influences prognosis and treatment strategy.

Treatment Options

Treatment is multimodal and tailored to stage, histology, patient age and overall health.

Surgery

The cornerstone is debulking (cytoreductive) surgery. Goals include removing the ovaries, fallopian tubes, uterus and any visible tumor deposits. In early-stage disease, a unilateral or bilateral salpingooophorectomy may be sufficient; advanced disease often requires a more extensive procedure.

Chemotherapy

Platinumbased regimens (carboplatin + paclitaxel) are standard. Intraperitoneal chemotherapy can be considered for selected Stage III patients. Targeted agents such as bevacizumab (antiVEGF) and PARP inhibitors (olaparib, rucaparib) have shown benefit, especially in BRCAmutated tumors.

Radiation

Rarely used as primary therapy, but may be employed for palliation or in selected early-stage cases.

Hormonal & Immunotherapy

Hormoneresponsive stromal tumors may respond to progestins. Emerging data on immune checkpoint inhibitors are promising, though not yet standard of care.

Side Effects and Management

Treatment can cause fatigue, nausea, neuropathy, bloodcount suppression, and menopausal symptoms. Supportive careantiemetics, growthfactor support, physiotherapy, and psychosocial counselinghelps maintain quality of life.

FollowUp and Survivorship

After initial treatment, patients undergo regular surveillance:

• Physical exam and symptom review every 36 months for the first 2 years, then annually.
• CA125 monitoring (if initially elevated) at similar intervals.
• Imaging (ultrasound, CT, or MRI) when clinically indicated.

Longterm survivorship issues include risk of recurrence, secondary malignancies, osteoporosis and psychosocial concerns. Lifestyle modificationsmaintaining a healthy weight, regular exercise and balanced nutritionare encouraged.

Prevention and Early Detection

While no guaranteed prevention exists, risk can be lowered by:

• Oral contraceptive use (510 years reduces risk by ~50%).
• Pregnancy and breastfeeding.
• Prophylactic salpingooophorectomy for highrisk women (e.g., BRCA carriers) after childbearing is complete.
• Genetic counseling and testing for families with strong cancer histories.

Living With Ovarian Cancer

Support networks, patient advocacy groups and clinical trials are valuable resources. Participation in research offers access to novel therapies and contributes to scientific advancement.

Key Takeaways

• Ovarian cancer often presents with nonspecific symptoms, making early detection challenging.
• Family history and genetic mutations (especially BRCA1/2) significantly increase risk.
• Standard treatment combines surgery and platinumbased chemotherapy; targeted agents improve outcomes for selected patients.
• Regular followup and survivorship care are essential for early identification of recurrence and management of longterm effects.
• Preventive strategies, including oral contraceptives and prophylactic surgery in highrisk individuals, can markedly lower incidence.

For personalized information, always consult a gynecologic oncologist or a qualified healthcare professional.